{
    "clinical_study": {
        "@rank": "82379", 
        "arm_group": {
            "arm_group_label": "Metatinib Tromethamine", 
            "arm_group_type": "Experimental", 
            "description": "Dose escalation is in accordance with the traditional \"3 +3\" design, and dose groups are subsequently set as: 25, 50, 100, 200, 300, 450, 600, 800 mg/d."
        }, 
        "brief_summary": {
            "textblock": "Primary Objective: To evaluate the safety, tolerability and maximum tolerated dose (MTD) of\n      daily oral administration of metatinib tromethamine in subjects with solid tumors;\n      Investigate the influence of food on pharmacokinetic parameters.\n\n      Secondary Objective: To evaluate the plasma pharmacokinetics (PK) of daily oral\n      administration of metatinib tromethamine in subjects with solid tumors; To observe\n      preliminary anti-tumor efficacy; To evaluate potential pharmacodynamic and predictive\n      biomarkers at MTD."
        }, 
        "brief_title": "Phase I Clinical Study of Metatinib Tromethamine Tablet", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced or Metastatic Solid Tumors", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Weight: male weight \u2265 45 kg; female weight \u2265 40 kg, body mass index (BMI) between\n             18~24 kg/m^2, including the boundary values;\n\n          -  The subject has a histologically confirmed solid tumor that is metastatic or\n             unresectable, and for which standard curative or palliative measures do not exist or\n             are no longer effective, and there are no known therapies to prolong survival;\n\n          -  Not treated with standard therapeutical regime currently, or has progressed or\n             relapsed after standard treatment;\n\n          -  Time from last cytotoxic chemotherapy (including investigational cytotoxic agents) or\n             biologic agents (immune modulators, cytokines) \u2265 4 weeks, or nitrosoureas or\n             mitomycin C \u2265 6 weeks. If having received an antibody anti-tumor biological product,\n             at least 8-week washout period is required;\n\n          -  At least 4 weeks after surgery, and the wound must be healed completely;\n\n          -  If subject has chemotherapy-induced toxicity, the adverse events must be recovered to\n             \u2264 grade 1 (NCI-CTC version 4.0) except for alopecia;\n\n          -  ECOG performance status of 0-2;\n\n          -  Expected survival time is more than three months;\n\n          -  The subject has organ and marrow function as follows:\n\n               1. absolute neutrophil count (ANC) \u2265 1.5 x 10^9/L,\n\n               2. platelets \u2265 80 x 10^9/L,\n\n               3. hemoglobin \u2265 90 g/L (blood transfusion is allowed),\n\n               4. total bilirubin \u2264 2 x ULN (<3 x ULN with liver metastases),\n\n               5. serum creatinine \u2264 150 \u03bcmol/L or calculated creatinine clearance \u2265 60 mL/min,\n\n               6. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 3 x ULN\n                  (<5 x ULN with liver metastases),\n\n               7. uric acid <500 \u03bcmol/L,\n\n               8. proteinuria \u2264 2 + or \u2264 2g / 24h;\n\n          -  The subject is capable of understanding and complying with the protocol and has\n             signed the informed consent document;\n\n        Exclusion Criteria:\n\n          -  The subject is known to be positive for the human immunodeficiency virus (HIV);\n\n          -  The subject is known to be positive for hepatitis B surface antigen or hepatitis C;\n\n          -  Previous participation in other clinical trials within three months before study;\n\n          -  Concomitant chemotherapy, hormone therapy, immunotherapy program or radiotherapy;\n\n          -  The subject has an uncontrolled intercurrent illness including, but not limited to,\n             ongoing or active infection, symptomatic congestive heart failure, unstable angina\n             pectoris, or cardiac arrhythmia;\n\n          -  The subject has psychiatric illness/social situations that would limit compliance\n             with study requirements;\n\n          -  The subject has brain metastases;\n\n          -  Imaging study showed involvement of major blood vessels or nerves by tumor;\n\n          -  Uncontrollable hypertension (referring to systolic blood pressure> 150 mmHg and / or\n             diastolic blood pressure> 100 mmHg after treatment) or LVEF <50%;\n\n          -  Patient with disease history of bleeding or thromboembolic events occurred within the\n             past six months and need for preventive anticoagulant therapy;\n\n          -  Patient needs surgery within 28 days, or is expected to require surgery within 28\n             days after the last dose administration;\n\n          -  Significant abnormality in the important organs, such as heart, lung, liver, kidney;\n\n          -  Has third lacunar effusion with difficulty to control;\n\n          -  The subject is pregnant or breastfeeding;\n\n          -  Sexually active subjects (male and female) refuse to use medically acceptable methods\n             of contraception during the course of the study and for 1 month following\n             discontinuation of study drug."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "49", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004548", 
            "org_study_id": "SIM-89-1"
        }, 
        "intervention": {
            "arm_group_label": "Metatinib Tromethamine", 
            "intervention_name": "Metatinib Tromethamine", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "last_name": "Feng Bi, MD", 
                "phone": "86-28-85423609"
            }, 
            "facility": {
                "address": {
                    "city": "Chengdu", 
                    "country": "China", 
                    "state": "Sichuan"
                }, 
                "name": "West China Hospital, Sichuan University"
            }, 
            "investigator": {
                "last_name": "Feng Bi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Multiple Dose Escalation Clinical Trial of Metatinib Tromethamine Tablet in Patients With Advanced or Metastatic Solid Tumors", 
        "overall_official": [
            {
                "affiliation": "West China Hospital", 
                "last_name": "Feng Bi, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "West China Hospital", 
                "last_name": "Maozhi Liang, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "West China Hospital", 
                "last_name": "You Lu, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "West China Hospital", 
                "last_name": "Qin Yu, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "West China Hospital", 
                "last_name": "Li Zheng, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Dose-limiting Toxicity (DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "up to day 32"
            }, 
            {
                "measure": "Maximum Tolerated Dose (MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "up to day 32"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004548"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "d1\u3001d2\u3001d3\u3001d8\u3001d15\u3001d22\u3001d29\u3001d30\u3001d31"
            }, 
            {
                "measure": "AUC", 
                "safety_issue": "No", 
                "time_frame": "d1\u3001d2\u3001d3\u3001d8\u3001d15\u3001d22\u3001d29\u3001d30\u3001d31"
            }, 
            {
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "week 4, week 10, week 16"
            }
        ], 
        "source": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}